GLP-1 Weight Management Programme

ATA Medical offers a structured, medically supervised weight management programme using GLP-1 receptor agonist medications for eligible adult patients. GLP-1 agonists — including semaglutide (available as weekly Wegovy injections, weekly Ozempic injections, or daily Rybelsus tablets) and tirzepatide — represent the most clinically effective pharmacological tools for sustained weight reduction currently available, with clinical trials demonstrating 15–22%…

Eligibility for GLP-1 therapy at ATA Medical follows established clinical criteria: adults aged 21 or older with a BMI of 30 or above (obesity), or a BMI of 27 or above combined with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea. The initial consultation (from SGD 49.05) includes a clinical assessment of weight history, dietary habits, comorbidities, and metabolic markers to…

Prior to initiating treatment, baseline blood tests are recommended to assess fasting glucose, HbA1c, lipid profile, liver function, kidney function, and thyroid status — all of which influence both treatment selection and response monitoring. InBody body composition analysis (SGD 43.60) provides a baseline measurement of fat mass, skeletal muscle mass, visceral adipose tissue, and hydration, establishing the starting point for tracking progress.